The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Aravive Inc. (ARAV) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.01, or 0.56%, to $1.80. The Aravive Inc. has recorded 51 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.79 and fluctuated between $1.8300 as its day high and $1.7200 as its day low. The current market capitalization of Aravive Inc. is $106.50M. A total of 98557.0 shares were traded on the day, compared to an average of 635.74K shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ARAV has seen 8 BUY and 0 SELL insider trades, representing the acquisition of 17,838,891 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 0 SELLs from insiders. Insiders purchased 23,244,562 shares during that period but sold 0.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for ARAV in the last 3 months, the mean price target is $9.80 with high estimates of $18.00 and low estimates of $2.00. In terms of 52-week highs and lows, ARAV has a high of $2.61 and a low of $0.58.
As of this writing, ARAV has an earnings estimate of -$0.64 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.54 per share and a lower estimate of -$0.69. The company reported an EPS of -$0.62 in the last quarter, which was -17.00% lower than expectations of -$0.53.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARAV is Overweight with a score of 5.00. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.